

Quick SARS-CoV-2 rRT-PCR Kit





### **Testing for COVID-19 Detection**

The Quick SARS-CoV-2 rRT-PCR Kit from Zymo Research is intended for the qualitative detection of nucleic acids from SARS-CoV-2 in upper and lower respiratory specimens from patients suspected of COVID-19 by their health care provider. The Quick SARS-CoV-2 rRT-PCR Kit is FDA Emergency Use Authorized (EUA) and has been granted with the CE-IVD mark.

## **Highlights**

- No cold-chain required for specimen transportation
- Compatible with automated and manual RNA extraction
- Targets the SARS-CoV-2 nucleocapsid (N) gene and the human RNaseP gene
- Limit of Detection (LoD) of 15 viral genome equivalent copies per reaction (GEC)/rxn
- Simple and fast reaction set-up with results in < 1.5 hours after RNA extraction

# The SARS-CoV-2 Testing Workflow Includes:

Sample Collection in DNA/RNA Shield™

RNA Extraction using Quick-DNA/RNA™ Viral MagBead Kit SARS-CoV-2 Detection using the Quick SARS-CoV-2 rRT-PCR Kit











Proprietary sample collection technology

- Store the sample at ambient temperature up to 7 days.
- No cold-chain required for shipping.
- Collection devices for upper and lower respiratory tract specimens.

Robust nucleic acid purification

- Compatible with manual and automated procedures.
- Automated RNA extraction in <
   <p>1 hour using the KingFisher™ Flex
   Purification System (ThermoFisher
   Scientific).

SARS-CoV-2 detection system

- Simple reaction set-up in less than 7 minutes: RNA is directly combined with the ready-to-use reaction mix and incubated in the CFX96 Touch Real-Time PCR Detection System (Bio-Rad).
- 100% detection at 15 GEC/rxn.
- Results in < 1.5 hours after extraction.
- Includes CV Mix 1 (for SARS-CoV-2 detection), CV Mix 2 (internal human control), CV Positive Control and No Template Control.

The Zymo Research FDA EUA workflow can be adopted by any authorized laboratory. Individual components of this workflow can be adopted for use in other SARS-CoV-2 testing systems, however, any modifications to the Zymo Research EUA workflow must be submitted for review to the FDA and may require additional validation in order to maintain the authorization status.

# **Specifications**

1

Specimens collected in DNA/RNA Shield™ are extracted manually or with the automated KingFisher™ Flex Purification System (ThermoFisher Scientific) using the script available at: www.zymoresearch.com/products/quick-sars-cov-2-rrt-pcr-kit



2

Samples are analyzed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad).



#### RT-PCR Set-up

Component	Volume per Reaction
CV Mix (1 or 2) Template RNA	10 μl 10 μl
Total	20 µl

Select **HEX** channel for the detection of SARS-CoV-2 targets (CV Mix 1) and **Quasar 670** for the detection of human target (CV Mix 2).

### Data Analysis & Interpretation

Interpret the results based on C, values


Host Target	Viral Target	Results
+	-	SARS-CoV-2 Negative
+	+	SARS-CoV-2 Positive*
-	+	SARS-CoV-2 Positive*
-	-	Invalid

<sup>\*</sup>A positive result using the *Quick* SARS-CoV-2 rRT-PCR Kit is considered presumptive for SARS-CoV-2 because it may result from infection by another Sarbecovirus, such as SARS-CoV. Follow-up testing may be performed if differentiation between targets is desired.

#### 3

#### Performance:

- PPA: 30/30 = 100% (95% CI: 88.7% 100%)
- NPA: 30/30 = 100% (95% CI: 88.7% 100%)
- 100% accurate detection as low as 15 GEC/rxn



# **Ordering Information**

	Catalog Number	Product Name	Size
	R1106 R1107	DNA/RNA Shield™ Collection Tube w/ Swab (1 ml fill)	10 pack 50 pack
Sample Collection	R1108 R1109	DNA/RNA Shield™ Collection Tube w/ Swab (2 ml fill)	10 pack 50 pack
	R1210	DNA/RNA Shield™ Saliva Collection Kit	1 x 2 ml fill
Sample Purification	R2140 R2141	Quick-DNA/RNA™ Viral MagBead Kit	1 x 96 preps 4 x 96 preps
SARS-CoV-2 Detection	R3011 R3011-1K R3011-10K	Quick SARS-CoV-2 rRT-PCR Kit	100 tests per kit 1,000 tests per kit 10,000 tests per kit

This test has not been FDA cleared or approved. This test has been authorized by the FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Detection of SARS-CoV-2 RNA may be affected by sample collection methods, patient factors, and/or stage of infection.



The **BEAUTY** of **SCIENCE** is to Make Things **SIMPLE**®



